Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Neoplasm Metastasis

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Liver Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Clinical Trials

LEAP-012

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SLIDE-HCC

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

EMERALD-3

CheckMate 9DW

REVIVE

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

FLEX-HCC

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

MK-3475-06B

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

HAIC-quad

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

BLP-HCC

LEAP-002

MK-7902-017

LENVABLA

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)